FLNA Stock Chart & Stats
$23.00
$0.00(0.00%)
At close: 4:00 PM EDT
$23.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$15.40 - $86.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$728.90M
Enterprise Value-$25.19
Total Cash (Recent Filing)$82.68M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.08
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding48,307,896
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.33
Price to Sales (P/S)0.00
P/FCF Ratio-3.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$87.20Price Target Upside279.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Minimal DebtNear-zero recorded debt provides durable financial flexibility for a pre-revenue biotech. Low leverage reduces bankruptcy risk and preserves ability to raise non-debt capital or pursue partnerships, supporting continued R&D investment without immediate interest burdens.
Governance Continuity & Incentive AlignmentRe-election of directors, approval of an omnibus incentive plan amendment, and auditor ratification signal governance stability and stronger compensation alignment. Stable board and equity incentives help retain management and align long-term R&D execution with shareholder interests.
Improved Cash Burn In 2025A marked reduction in operating cash outflow in 2025 versus 2024 suggests improved cost control or program prioritization. Lower burn extends runway and reduces near-term financing pressure, increasing the odds management can advance programs before raising incremental capital.
Bears Say
Zero Revenue (development-stage)No product revenue across multiple years means valuation and future cashflows depend solely on R&D success or partnerships. This creates binary commercial risk and sustained funding dependence, limiting operating stability and making medium-term outcomes highly uncertain.
Persistent Large Operating LossesMaterial and volatile annual losses, including a large deterioration in 2025, imply ongoing high cash needs. Persistent deficits erode equity and force frequent capital raises or dilutive financings, constraining long-term planning and increasing shareholder dilution risk.
Shrinking Equity And AssetsSteady declines in equity and total assets signal eroded financial cushions and reduced ability to absorb trial setbacks or fund parallel programs. A smaller balance sheet increases reliance on external capital and limits strategic optionality over the medium term.
Filana Therapeutics News
FLNA FAQ
What was Filana Therapeutics’s price range in the past 12 months?
Filana Therapeutics lowest stock price was $15.40 and its highest was $86.00 in the past 12 months.
What is Filana Therapeutics’s market cap?
Filana Therapeutics’s market cap is $728.90M.
When is Filana Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Filana Therapeutics’s earnings last quarter?
Currently, no data Available
Is Filana Therapeutics overvalued?
According to Wall Street analysts Filana Therapeutics’s price is currently Undervalued.
Does Filana Therapeutics pay dividends?
Filana Therapeutics does not currently pay dividends.
What is Filana Therapeutics’s EPS estimate?
Filana Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Filana Therapeutics have?
Filana Therapeutics has 48,307,896 shares outstanding.
What happened to Filana Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Filana Therapeutics?
Currently, no hedge funds are holding shares in MX:FLNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Filana Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.68%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-23.11%
Trailing 12-Months
Company Description
Filana Therapeutics
Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.
FLNA Stock 12 Month Forecast
Average Price Target
$87.20
▲(279.14% Upside)